• Utah-based Diamond Lake Minerals Inc. is a vertically integrated company focused on digital assets and securities, focused on building and acquiring enterprises in sectors ranging from music and entertainment to real estate, healthcare, and digital tokens
• The company has welcomed a new CEO and several new strategic advisors since late August, building market value to $84 million in market cap
• One of DLMI’s aims is to be a “hybrid missing piece”, getting generational wealth to overcome modernization acquisition hurdles and become involved in the digital assets space

Multi-strategy operating company Diamond Lake Minerals (OTC: DLMI) is building a digital vision for the future on a foundation that includes decades of experience in diverse market sectors, as represented by the company’s new executive team.

The team’s background includes experience in manufacturing, technology, music, real estate, smart cities, blockchain, agriculture, mining, technology, legalized gaming, and hotel resorts, along with the business acumen acquired through those ventures.

“The reason why a lot of these amazing people are part of this team is taking the business models of the traditional world and then … combining that with what I know is the future of securities, and that’s digital assets or digital securities,” CEO Brian J. Esposito, who joined the company in late August, said in a Bell2Bell podcast earlier this month (https://ibn.fm/UCZQn).

“So when you start to look at where are we going as it relates to bringing assets in the digital environment such as securities, I believe DLMI is the hybrid missing piece to get generational wealth, or the wealth on the sidelines — (people) that hear about digital assets,” Esposito said.

“Their kids are involved with it. They hear about it at work. … Maybe they don’t trust it, maybe they don’t understand it, or they’re insecure about it, they don’t know how to download a digital wallet. So what we’re building is the ability to be involved in that space, through a regulated environment,” he added. “So we’re combining old-school traditional business models with new-school mechanisms such as security tokens to provide value to our companies and our holdings that are coming in, and ensure consistent value and sharing those earnings with our shareholders.”

Esposito noted that the company’s market value has been a strong indicator of its potential, as it went from a historic position of “around a million dollars” before he took the reins as CEO to an additional $80 million to $84 million in market cap during the two months since then, while having the full support of these recently announced iconic advisors:

• Agnes Budzyn, the Managing Partner of Bluedge Ventures
• Anthony Scaramucci, the founder and managing partner of SkyBridge
• Larry Namer, the founder of E! Entertainment TV and President of Metan Global
• Michael J. Malik Sr., a prominent entrepreneur and leader in casino development
• Andrew Fromm, founder of Fromm Consulting
• Brandon Fugal, Chairman of Colliers International in Utah
• Raul Leal, CEO of SH Hotels & Resorts

DLMI’s industry-agnostic holding strategy, establishing a vertically integrated ecosystem through starting, acquiring and building “wonderful entities,” emphasizes transparency, liquidity and security in the familiar investment vehicle of stocks.

“We’ll have media, we’ll have healthcare, we’ll have things that operate in security tokens, in digital assets. We’ll have music and IP, we’ll have the entertainment industry, we’ll have real estate opportunities,” he said. “And (we’ll be) doing that in the correct fashion and showing how all of these different holdings will share resources, support one another, and ensure that if there’s a downside in one industry or segment, that we have a diversified model to help keep everything afloat and everything growing.”

In the end, Esposito said his aim is to look out for those invested in the company.

“I want our company to create a new benchmark on how public companies should be communicating,” Esposito said. “I love working in the regulated environment because it’s a place that helps ensure protecting people.”

For more information, visit the company’s website at www.DiamondLakeMinerals.com, or LinkedIn page at www.LinkedIn.com/company/Diamond-Lake-Minerals/.

NOTE TO INVESTORS: The latest news and updates relating to DLMI are available in the company’s newsroom at https://ibn.fm/DLMI

• Arizona-based SenesTech Inc. provides a unique approach to rodent pest control by formulating a contraceptive that works as birth control in both male and female rats
• A major milestone has been reached by the company as it recently began taking orders for its new Evolve(TM) Soft Bait formulation, which joins SenesTech’s liquid ContraPest(R) brand as a population-control solution that avoids some of the problems associated with lethal rodenticides
• The Evolve(TM) Soft Bait product is targeting the vast professional pest control market that prefers a non-liquid product, as well as providing a consumer-friendly option that may be marketed through big box retailers and e-commerce providers
• SenesTech’s operation has been growing rapidly this year, and company officers stated last month that its “pro forma cash balance” is $4 million with no long-term debt

With the advent of cooler weather in the Northern Hemisphere, rodents become more noticeable in homes and buildings as they seek warmer refuge. Pest control giant Orkin estimates mice and other rodents invade around 21 million homes across the United States each fall, according to its annual report on the “50 rattiest cities” (https://ibn.fm/0X9O6).

Rodent control innovator SenesTech (NASDAQ: SNES) is using its own unique approach to the science of reducing rat populations to help clients and pest control companies enjoy the holiday season without such unwanted guests. They have developed a means of birth control for the rodents that keeps their populations from growing, allowing their numbers to dwindle generationally.

“The existing lethal solutions’in the marketplace are limited by rats’ reproduction rates, resistance and aversion, as well as the enhanced social and political limitations on the use of poison,” SenesTech CEO and President Joel Fruendt said during a webcast interview last month at the Lytham Partners Fall 2023 Investor Conference (https://ibn.fm/PxfA6).

The company is building on its initial successes with its trademarked liquid ContraPest(R) bait by recently introducing companion brand Evolve(TM) Soft Bait, which gives SenesTech a non-liquid formulation for its portfolio. Non-liquid solutions make up 90 to 95 percent of the rodent control market and are preferred by professional exterminators, according to Fruendt, so the Evolve bait presents the company with the possibility of exponential revenue growth.

“We’ve experienced rapid growth over the past few years,” CFO Tom Chesterman said during the Lytham webcast. “Most recent trends confirm that growth is accelerating as our initiatives put place in the first half of the year take hold. … At the end of June, we had $2.2 million in cash but in August we closed on a warrant exercise, which brought in an additional $2.1 million gross proceeds. Netted expenses, our pro forma cash balance, would be $4 million.”

Evolve is highly palatable to rats, easy to deploy, and can be placed in a wide variety of environments including municipal buildings, parks, recreation facilities, sports venues, food processing facilities, correctional facilities, subways, medical facilities, agribusiness, zoos and residential locations, the company stated in a news release announcing the soft bait’s availability (https://ibn.fm/E7CA6).

The company recommends placing the contraceptive bait in tamper-resistant stations to limit exposure for non-targeted species, but adds that the low levels of the active ingredient are specifically suited to rats’ body masses and larger mammals would only see effects if they repeatedly ingest a substantial amount over several weeks, while small birds appear more tolerant of it because of their distinct digestive systems.

“Evolve’s active ingredient, gossypol, derived from cottonseed, has a well-documented record of efficacy, and was developed under the EPA’s minimum risk rules, also known as ’25B'”, CTO Dan Palasky stated in the news release. “We will be publishing a white paper summarizing this data, as well as continuing to perform our own field tests.”

Previous field tests using the liquid ContraPest formulation targeted West Coast and East Coast poultry farms. Rat populations were evaluated monthly over the course of a year, and the company found that in the West Coast study ContraPest cut the rat population in half in three months and produced a sustained 90 percent reduction over the 12-month study. In the East Coast study, the client reported an 88 percent improvement in the survival of the baby chicks after reducing the rat population with ContraPest.

Fruendt said the East Coast client projected $600,000 in increased revenue as a result of using ContraPest, following on an investment of $10,000 to incorporate ContraPest into its pest management program, marking a significant ROI.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

• Clene, a company targeting the treatment of neurodegenerative diseases that severely impact people’s lives, is currently focusing on amyotrophic lateral sclerosis (“ALS”) alongside other neurodegenerative diseases
• The company’s wholly owned subsidiary, Clene Nanomedicine, and two collaborators, Columbia University and Synapticure, are the recipients of a four-year grant totaling $45.1 million
• The grant will support an Expanded Access Protocol (“EAP”) study for Clene’s investigational product, CNM-Au8(R)
• CNM-Au8 is an orally administered gold nanocrystal suspension that is thought to improve mitochondrial health and protect neuronal function to treat neurodegenerative diseases, including ALS
• The EAP study will give patients who did not initially meet the criteria to enroll in a clinical trial an opportunity to try CNM-Au8, which, besides being well tolerated, has improved the survival of ALS patients

In late December of 2021, President Biden signed into law H.R. 3537, the Accelerated Access to Critical Therapies for ALS Act (“Act for ALS”) (https://ibn.fm/oQbSk). The Act for ALS (amyotrophic lateral sclerosis), now public law, directs the Department of Health and Human Services through the Secretary to, among others, “award grants to participating entities for the purposes of scientific research utilizing data from expanded access to investigational drugs for individuals who are not otherwise eligible for clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS” (https://ibn.fm/A2Tuu).

During the financial year 2023, the National Institutes of Health (“NIH”) made strides to implement the Act for ALS, extending its commitment to advancing research on ALS, which currently has no cure. Through its division, the National Institute of Neurological Disorders and Stroke (“NINDS”), the NIH issued three new awards for the grant program prescribed in the Act for ALS (https://ibn.fm/c1Dcb). One of these awards, a four-year grant totaling $45.1 million, went to Clene Nanomedicine Inc., a wholly owned subsidiary of Clene (NASDAQ: CLNN), and its collaborators, Columbia University and Synapticure.

The funding is intended to support an EAP study investigating the safety and efficacy of Clene’s investigational product (“IP”), CNM-Au8, as a treatment for people with ALS (https://ibn.fm/rvyaD). Researchers will use this funding to offer the drug to patients living with ALS across varied clinical sites across the United States and through a telemedicine neurology clinic (a virtual clinic) operated by Synapticure, according to official communication published on NINDS’s website. Synapticure’s virtual clinic and network of nationwide clinics will facilitate the participation of ALS patients from all 50 states, including those living in rural and remote areas.

The study’s designed scope aligns with the Expanded Access pathway, which enables patients with ALS – or any other serious and life-threatening disease – to access an IP, like CNM-Au8, that has not yet been approved by the U.S. Food and Drug Administration (“FDA”). Also known as Compassionate Use, the EAP gives patients who did not initially meet the criteria to participate in a Clene clinical trial an opportunity to try the IP, in this case, CNM-Au8.

CNM-Au8 is an orally administered gold nanocrystal suspension that is thought to improve mitochondrial health and protect neuronal function to treat neurodegenerative diseases. This IP, which clinical studies have shown is well tolerated, can penetrate the blood-brain barrier, stimulate energy production and utilization, and reduce oxidative stress in cells. Its creation resulted from Clene Nanomedicine’s discovery that gold has extraordinary catalytic and therapeutic properties when engineered as highly faceted clean-surfaced nanocrystals.

“The surfaces of gold nanocrystals, among other capabilities, are able to rapidly catalyze nicotinamide adenine dinucleotide (‘NAD’), a key energy metabolite. This catalytic reaction drives the production of adenosine triphosphate (‘ATP’), the cellular currency of energy… By replenishing neuronal energy supply, CNM-Au8 protects neurons from disease and death, helping them survive and function,” explains a video on Clene’s website (https://ibn.fm/WnFGz).

Clene has previously demonstrated evidence of consistent safety and improved survival for CNM-Au8 across a broad ALS population in two independent Phase 2 trials and ongoing ALS EAP programs that have enrolled over 200 participants since 2019. “This new EAP provides access to CNM-Au8 for more people living with ALS and enables the collection of survival, safety, and biomarker data in a population not studied in clinical trials,” commented Benjamin Greenberg, M.D., MHS, FAAN, Head of Medical of Clene. “These data can help provide confirmatory support for the existing trial data Clene has gathered in its clinical trials.”

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• The agreement with GEDiCube rebrands the company as a wholly-owned subsidiary under the name Renovaro.AI
• The combined company brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early detection, diagnostic insights, and targeted immunotherapies, for cancer and other diseases
• The AI division intends to launch commercial products for early cancer detection and improved therapy selection in 2024 – rapidly expanding the largely untapped precision medicine market

In September, Renovaro Biosciences (NASDAQ: RENB), an advanced, preclinical biotechnology company focused on cell, gene, and immunotherapy, and GEDiCube Intl Ltd., an AI medical technology company, announced a definitive agreement for combination. Under the stock-for-stock agreement, GEDiCube will become a wholly-owned subsidiary of Renovaro. The company’s CEO, Dr. Mark Dybul, MD, recently sent a letter to Renovaro shareholders to provide an update on the union – sharing the vision of the combination and expressing appreciation for their ongoing support and investment (https://ibn.fm/yFhPk).

“We believe GEDiCube’s AI technology will enhance and accelerate the development of treatments we are currently pursuing as well as power the discovery of new therapeutic approaches for cancer and other diseases,” press releases from the combination announcement quote Dr. Dybul as saying (https://ibn.fm/V1UyG). “The combined company will have independent operating divisions that will allow each technology to move as quickly as possible to commercialization while the collaboration between divisions will aim to drive new advances in both AI and medicine.”

According to Dr. Dybul, the AI division intends to launch commercial products for early cancer detection and improved therapy selection in 2024 – rapidly expanding the precision medicine market, which Renovaro is positioned to capture a substantial share of the largely untapped market.

The immunotherapy division plans to start Phase 1/2 trials of its lead asset in the second half of 2024, a breakthrough approach Dr. Dybul believes could lead to emergency use authorization as soon as the end of 2027 – following the results of a Phase 2 clinical trial that will transform treatment for cancers with low survival rates, like pancreatic cancer.

The combined company brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early detection, diagnostic insights, and targeted immunotherapies. GEDiCube’s award-winning AI technology has already shown the ability to detect lung cancer early with 95% accuracy by analyzing complex molecular data. The company’s proprietary platform searches for patterns across genomics, epigenomics, transcriptomics, and other omics layers to identify informative biomarkers for over 12 cancers thus far. The company will rebrand as Renovaro.AI as outlined in the combination agreement.

Renovaro’s strength is its advanced immunotherapy platform focused initially on some of the deadliest solid tumor cancers that have seen only marginal improvement in survival rates over the past several decades. The company’s patented approach modifies allogeneic dendritic cells to stimulate anti-tumor immunity specific to a patient’s genetic profile. Remarkably, Renovaro’s personalized vaccine technology has shown an 80-90% reduction in tumor size, and the company expects to start human trials during the second half of 2024.

In his letter to the company’s shareholders, Dr. Dybul underlines that, like any cutting-edge company, there will be challenges ahead – but that the need has never been greater for transformative solutions that the combination of Renovaro and GEDiCube can provide. Dr. Dybul believes that there is a vision, technology, and talent that can transform how cancer is detected and managed early on. The companies have an opportunity and responsibility to fundamentally transform the lives of patients and families across the globe and help define the future of medicine.

For more information, visit the company’s website at www.RenovaroBio.com.

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

• Freight Technologies announced securing a Request for Quotation from a leading global pharmaceutical giant that awards the company 33 lanes of transport pharmaceutical goods from the United States to Canada and Mexico
• The Request for Quotation extends over seven months, and Fr8App will provide uninterrupted, end-to-end logistics solutions, including secure transport, tracking, and reporting for each load
• The company’s dedicated team of professionals will oversee this vital operation to guarantee the smooth and efficient delivery of the pharmaceutical company’s critical products

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a technology company developing solutions to optimize and automate the supply chain process through its custom-developed, industry-leading freight-matching platform powered by AI and machine learning, recently announced securing a Request for Quotation (RFQ) from a leading global pharmaceutical giant. The pharmaceutical conglomerate is known for its commitment to global health and life-changing innovations and has chosen Fr8App as its trusted partner for crucial logistical operations (https://ibn.fm/vyOgV).

Under the terms of the RFQ, Fr8App has been awarded 33 lanes of transport pharmaceutical goods from the United States to Canada and Mexico. The project involves moving one to three loads daily per lane, ensuring timely and secure delivery of vital pharmaceutical products to their international locations. The project is a testament to Fr8Tech’s commitment to safety, reliability, and precision in logistical operations.

Javier Selgas, CEO of Fr8Tech, said, the company was proud and honored to have been chosen to undertake this vital logistics operation. “This achievement represents a significant step in our mission to provide world-class logistics services, especially in the pharmaceutical industry, where precision and reliability are paramount,” Selgas said. “Our team is ready and excited to meet the high expectations of our esteemed client.”

The duration of the RFQ extends over seven months, during which time Fr8App will provide uninterrupted, end-to-end logistics solutions, including secure transport, tracking, and reporting for each load. The company’s dedicated team of professionals will oversee this vital operation to guarantee the smooth and efficient delivery of the pharmaceutical company’s critical products.

Fr8Tech offers an entire solutions suite to shippers and carriers that leverages AI to provide cloud-based platforms aiming to automate over-the-road transportation processes. The suite effectively reduces human touch points, expedites load booking times, and includes:

• Fr8App – a B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
• Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
• Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates, and proof of deliveries
• Fr8FMS – A fleet management system allowing transportation companies to manage their fleets better, reduce operational costs, and provide better service to their customers
• Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers to increase visibility and control while supporting better business decisions
• Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

The services available to shippers and carriers make it possible for Fr8Tech to showcase their extensive expertise and offering – making over-the-road transport more efficient and affordable. With the RFQ win, Fr8App continues to solidify its presence in the competitive logistics market while establishing itself as a trusted partner for global companies looking for the secure services it provides.

For more information, visit the company’s website at www.Fr8Technologies.com and its freight-matching platform information site at www.Fr8.App.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

Leading industry academics, practitioners, and engineers, will gather at the QuantMinds International  2023 conference in London from November 13-16, 2023. They will discuss and share in-depth insights into the latest trends and cutting-edge technologies in quant finance for better scope in their future endeavours. Over 500 industry practitioners and academics, 110+ asset managers, and 8 out of the 10 top banks of Europe are expected to grace the event.

On the opening day of the summit on November 13, 2023, numerous workshops and interactive sessions will be held as follows:

• LLMs & Advanced ML Summit: Learn about the innovative applications, and join in the discussions to learn about future technologies
• Quant Invest Summit: Top bankers discuss tips to shape your quant fund, talking about topics ranging from Multi-Asset Class Investing to Tick Data Management
• Machine Learning and Finance Workshop:  Learn about the core issues and acquire skills in this field
• Volatility Modelling Workshop: Dr Julien Guyon will speak on volatility derivatives to variance curve models and rough volatility

For day 2, the main conference will feature speaker sessions and boardroom discussions on a wide spectrum of topics in this industry. Discuss the career of young quants, diversity and inclusion, model risk management practices for NLP, and more, at informative roundtable discussions, with guidance from quantitative analysis experts and bankers of reputed firms.

The esteemed speaker panel includes representatives from JP Morgan, BlackRock, Bank of America, University of Oxford, Bank of England, Citigroup, Barclays, MUFG, and more.

The conference will offer networking breaks where attendees can interact and connect with experts and peers for future business opportunities. Expert research and practitioner insights on applications of AI and ML technologies in quant will be a major area of discussion. 

To know more, please visit https://ibn.fm/wrCOn.

• The digital assets market is expected to reach US$56.42 billion by the end of 2023
• Diamond Lake Minerals’ mission is to facilitate SEC-registered tokens that allow people to easily invest, through stock, in an industry that can otherwise be confusing to newcomers
• The company offers investors cutting-edge technology, an experienced team, market potential, regulatory compliance, and a diverse portfolio

Digital assets are any valuable digital or virtual item, including cryptocurrency, digital tokens, non-fungible tokens (“NFTs”), and more, created, stored, and traded on a digital platform like blockchain. These digital assets are bought, sold, and traded like traditional assets. By the end of 2023, the digital assets market is expected to reach US$56.42 billion – driven by several factors transforming capital markets worldwide (https://ibn.fm/sodyF).

Diamond Lake Minerals (OTC: DLMI) is focused on a specific type of digital asset, SEC-registered security tokens, a form of cryptocurrency that represents fractions of assets that have real value (such as equity, a company, or real estate). The company is setting a new industry standard – with a mission of registering security tokens with the Securities and Exchange Commission (“SEC”) to ensure a legitimate and secure trading environment. Diamond Lake Minerals is committed to ensuring that all market participants can invest confidently by operating under a strict regulatory framework that adheres to guidelines set by various U.S. regulators.

When investing in Diamond Lake Materials, investors get the unique opportunity to invest in digital assets without the requirement of learning all of the details associated with this often-complex digital asset space. The company’s approach allows investors to gain exposure to the fast-growing digital security market through a familiar investment vehicle – purchasing stock.

Diamond Lake Materials offers investors:

• Cutting-edge Technology – employs state-of-the-art technology to develop and support digital assets and SEC-registered security tokens, setting a new standard for security and compliance.
• Experienced Team – Diamond Lake Minerals’ management team brings decades of diverse industry experience, which adeptly steers the company’s strategic direction in the digital asset space.
• Market Potential – the focus on SEC-registered security tokens positions the company to capture significant market shares in the rapidly growing digital asset ecosystem.
• Regulatory Compliance – Diamond Lake Minerals is committed to adhering to SEC regulations to ensure the legality of operations and instilling investor confidence.
• Diverse Portfolio – Even though the company primarily focuses on security tokens, its interests in other digital assets offer diversified investment potential.

The recent additions to the company’s board of directors position the company to dominate the digital asset space. The board and new CEO represent decades’ worth of experience in the industry with leadership roles to guide the company’s approach. The appointment of Brian J. Esposito as the company’s new CEO brings the backing of Esposito Intellectual Enterprises and its diverse access to the expertise of over 110 companies and 200 joint ventures, alongside the knowledge of over 25 industries.

As the digital asset industry transforms and evolves, Diamond Lake Minerals has created a business model that allows investors to take part in investing in digital assets through a hands-off approach – through the purchase of stock. The company is reducing the risk of not understanding the industry and allowing investors to become a part of a growing revolution in the digital security industry.

For more information, visit the company’s website at www.DiamondLakeMinerals.com, or LinkedIn page at www.LinkedIn.com/company/Diamond-Lake-Minerals/.

NOTE TO INVESTORS: The latest news and updates relating to DLMI are available in the company’s newsroom at https://ibn.fm/DLMI

• Lexaria, a global innovator in drug delivery platforms, recently announced plans to launch new human and animal studies examining whether its patented DehydraTECH(TM) technology can make GLP-1 drugs better
• Lexaria has previously demonstrated DehydraTECH’s overall potential in its DIAB-A22-1 animal study, which yielded weight loss, and improved triglyceride and cholesterol levels among diabetic-conditioned animals
• The company plans to replicate the results from this study while also exploring ways to improve the overall bioavailability of GLP-1 drugs for diabetes treatment and weight loss
• Lexaria management is optimistic that it will build on previous studies, replicate previous positive results, and improve the overall efficacy of GLP-1 drugs

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced plans to launch new human and animal studies that seek to examine its patented DehydraTECH(TM) technology’s potential on GLP-1 drugs for the treatment of diabetes and weight loss. This announcement follows the recent study results published on “New England Journal of Medicine,” which showed that 49 to 52 pounds weight loss was a common outcome across the 2,539 adult study participants (https://ibn.fm/ffvaN).

DehydraTECH has demonstrated, in many instances, significant improvement in how active pharmaceutical ingredients (“APIs”) enter the bloodstream with its strong bioavailability enhancing capabilities. Its unique and revolutionary approach has seen Lexaria granted 37 patents for the technology, ultimately safeguarding its applicability, given its growing list of applications ranging from nicotine delivery to NSAIDs, antiviral drugs, cannabinoids, vitamins, and more.

So far, DehydraTECH has demonstrated positive results in diabetes-related studies. Its DIAB-A22-1 animal study yielded at least three positive outcomes: weight loss plus improved triglyceride and cholesterol levels. Reduced body weight, specifically, was realized in just four days after the start of dosing with DehydraTECH-CBD, with peak results achieved nine days after dosing and maintained throughout the 8-week study duration (https://ibn.fm/2OIdi).

Lexaria looks to replicate these results with GLP-1 drugs while also exploring ways to make these drugs better. GLP-1 agonists have been known to help manage blood sugar levels in people with type 2 diabetes. They have also proven effective in treating obesity, a result which has been very much welcomed by consumers and the more than 37 million Americans currently living with diabetes. By doing so, Lexaria looks to carve out a significant market share in the diabetes drug market, projected to hit $82.93 billion in value by 2027 (https://ibn.fm/EbDOH).

This commitment builds on the work that Lexaria has been doing with DehydraTECH since 2014. It also reflects the technology’s potential and the company’s confidence in it. Thus far, studies have shown exceptional results, asserting Lexaria as a dominant figure in the drug delivery technology space. Its management is optimistic that as it heads into GLP-1 research, it will build on its previous studies, ultimately improving the overall efficacy of GLP-1 drugs and further demonstrating DehydraTECH’s potential.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Join the leading Industry practitioners and experts from all over the globe at the QuantMinds International 2023 at the InterContinental O2, London, November 13-16. The event will host 8 out of the 10 top banks of Europe. The event platform will witness over 500 top industry practitioners and academics with over 110 asset managers. The quant event will also feature the applications of AI and ML technologies in quant.

New players, freshers, and upcoming firms, can avail this important opportunity to learn new practices and insights in quant, namely pricing and volatility, alpha generation, and machine learning, from thought leaders and experts of global acclaim.

The conference offers:

• A huge networking opportunity to connect with the industry peers, and learn the intricacies of quant from the stalwarts attending the event
• Expert research and practitioner insights on derivatives & volatility, portfolio optimization, computational finance, credit risk, alpha investing, inflation & interest rates, model risk, regulation & clearing, and more
• Insights on macro trends and micro developments to take your projects ahead in 2023
• Tips from the advisory board that includes representatives of Bloomberg L.P., University of Leuven, University of Sussex, MUFG, Citi, Amundi, University of Oxford, Commerzbank AG & more!
• Personal discussions, interactive Q&A with speakers, and dedicated networking breaks where attendees can network with each other
• In-depth analysis and insights on interest rates, crypto risks, FX and commodities, automation in the equity market and much more

After the Chair’s welcome remarks, the panel will discuss the regulatory report for 2024, followed by a discussion on the use of quantum for collateral optimization, will AI and ML replace quants, and more.

For additional information, visit https://ibn.fm/wrCOn.

• D-Wave’s new open-source demonstration highlights how its Advantage(TM) quantum computing system can be used to tackle challenges in wireless channel decoding, a growing worldwide problem given the dramatic global growth in wireless connections
• Demonstration shows quantum computing’s ability to tackle challenges of this magnitude relative to classical computation
• Quantum and quantum-hybrid technologies offer value in helping network providers solve a variety of telco-related optimization problems

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software and services, and the world’s first commercial supplier of quantum computers, recently announced the launch of a new open-source demonstration that highlights how its Advantage(TM) annealing quantum computing system can be used to tackle wireless channel decoding problems. The demo, available through the company’s Leap(TM) real-time quantum cloud service, identifies solutions for increasing transmission capacity for wireless and cellular networks using coordinated multipoint decoding.

As the number of mobile connections worldwide approaches 12 billion, the wireless industry requires new solutions to ensure high-quality service levels while reducing operational costs and power requirements. This newly launched demonstration shows how D-Wave’s annealing quantum processing unit (“QPU”) can improve transmission performance and reduce transmission errors, particularly in dense urban areas characterized by high noise and load. D-Wave’s demo runs in a Jupyter notebook, accessible on GitHub (https://ibn.fm/SIrGM) and the Leap quantum cloud service (https://ibn.fm/JgISJ).

Trevor Lanting, vice president of software, algorithms, and cloud services at D-Wave, said a wide variety of companies spanning a diverse set of industries recognize the value D-Wave’s technology can bring to driving operational excellence (https://ibn.fm/RKqQY). “In the world of wireless telecommunications, the high degree of complexity and large number of variables means a massive amount of computational power is required to solve challenging problems like increasing transmission capacity,” Lanting explained. “Our demonstration shows how well our annealing quantum computing system can tackle challenges of this magnitude relative to classical computation, which could be transformative to network service providers.”

The demonstration is the latest example of the company’s practical applicability of its quantum and quantum-classical hybrid solutions for the telecommunications industry. D-Wave recently announced work with LG U+, the Korea Advanced Institute of Science and Technology (“KAIST”), and Qunova Computing to propel the development of 6G low-earth-orbit satellite networks through connectivity of ground-to-satellite links (“SGLs”) and inter-satellite-links (“ISLs”). Other telecom-related applications that can benefit from the company’s quantum technologies include: employee scheduling for workforce resource management, network design and expansion planning, call center routing, scheduling and routing service vehicles, and more.

D-Wave’s customers interface with the company’s Advantage quantum computer through its Leap cloud service, which delivers real-time cloud-based access with enterprise-class performance and scalability. Using Leap, customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail, and transportation, eliminating the need to wait hours, days, or even weeks to get viable answers to various problems. Its customer success stories demonstrate the company’s real-world value at a business scale (https://ibn.fm/8QmwS).

The company’s relentless pursuit of practical quantum computing has resulted in its technology being used by some of the world’s most advanced enterprises, including numerous Forbes Global 2000 companies. Commercial customers include blue-chip industry leaders like Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, Accenture, BBVA, NEC Corporation, Pattison Food Group Ltd., DENSO, and Lockheed Martin. D-Wave owns one of the largest quantum computer intellectual property portfolios in the industry, including more than 210 issued U.S. patents and more than 100 peer-reviewed papers in leading scientific journals.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements:

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential of D-Wave’s technology to improve transmission performance and reduce transmission errors and to out-perform classical computational methods with respect to challenges facing the telecom industry. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including whether the demonstration is successfully translated into production use-cases; general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of the company’s solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on the company’s business; the risk that the company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the company may never achieve or sustain profitability; the risk that the company is unable to secure or protect its intellectual property; volatility in the price of the company’s securities; the risk that the company’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. D-Wave undertakes no duty to update this information unless required by law.